Brief: Bioporto Says U.S. FDA Does Not Recommend That Co Pursue An EUA For NGAL Assay

BioPorto A/S

19/11/2021 16:16

Nov 19 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * BIOPORTO - U.S. FDA DOES NOT RECOMMEND THAT CO PURSUE AN
EUA FOR
NGAL ASSAY FOR PREDICTION OF RENAL REPLACEMENT THERAPY IN
COVID-19 PATIENTS
    * DECIDED NOT TO PURSUE AN EUA FOR AN NGAL ASSAY WITH THIS
APPLICATION FOR COVID-19 PATIENTS

Source text for Eikon:  ID:nGNE6xq87y 
Further company coverage:  BIOPOR.CO 

 ((Reuters.Briefs@thomsonreuters.com;;))